Will China’s bid for the COVID-19 vaccine be profitable?



[ad_1]

Life in China has more or less returned to normal.

Despite being the first country in the world to be affected by the COVID-19 virus, the government is currently reporting low infection rates, which it attributes to roadblocks and movement restrictions, most of which have eased since then.

There has also been a large-scale immunization program. More than a million people in China have received vaccinations, including healthcare workers, soldiers and diplomats.

Zheng Zhongwei, director of the Science and Technology Development Center of the China National Health Commission, explained the focus on television.

He said: “An emergency use authorization, which is based on China’s vaccine management law, allows unapproved vaccine candidates to be used among people who are at high risk of becoming infected for a limited period.”

The technology used by Chinese vaccine formulas is similar to that used to inoculate people against diseases like polio.



[ad_2]